SIRT1 and mantle cell lymphoma: Two alkylating agents, bendamustine and a metabolite of cyclophosphamide (4-hydroperoxy-cyclophosphamide, 4-OHCY) induce H3K18 acetylation and decrease the expression of SIRT1, SIRT7, and HDAC3 in a dose-dependent manner in mantle cell lymphoma (MCL) cells [151].